Previous close | 164.20 |
Open | 159.00 |
Bid | 158.15 x 100 |
Ask | 158.70 x 300 |
Day's range | 152.25 - 164.06 |
52-week range | 110.45 - 211.13 |
Volume | |
Avg. volume | 482,972 |
Market cap | 8.843B |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | 214.00 |
EPS (TTM) | 0.74 |
Earnings date | 31 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 204.62 |
Detailed Analysis of Repligen's Financial Performance and Market Positioning
Repligen (RGEN) delivered earnings and revenue surprises of -3.45% and 1.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-yearIncreased Filtration (non-COVID) revenue by 12% year-over-yearAchieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The compa